Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria

医学 肝细胞癌 米兰标准 肝移植 移植 外科 内科学 癌 胃肠病学
作者
Young Kim,Christopher C. Stahl,Abouelmagd Makramalla,Olugbenga Olanrele Olowokure,Ross L. Ristagno,Vikrom K. Dhar,Michael Schoech,Seetharam C. Chadalavada,Tahir Latif,Jordan R. Kharofa,Khurram Bari,Shimul A. Shah
出处
期刊:Surgery [Elsevier BV]
卷期号:162 (6): 1250-1258 被引量:30
标识
DOI:10.1016/j.surg.2017.08.007
摘要

Background Orthotopic liver transplantation is a curative treatment for hepatocellular carcinoma within Milan criteria, but these criteria preclude many patients from transplant candidacy. Recent studies have demonstrated that downstaging therapy can reduce tumor burden to meet conventional criteria. The present study reports a single-center experience with tumor downstaging and its effects on post–orthotopic liver transplantation outcomes. Methods All patients with hepatocellular carcinoma who were evaluated by our multidisciplinary liver services team from 2012 to 2016 were identified (N = 214). Orthotopic liver transplantation candidates presenting outside of Milan criteria at initial radiographic diagnosis and/or an initial alpha-fetoprotein >400 ng/mL were categorized as at high risk for tumor recurrence and post-transplant mortality. Results Of the 214 patients newly diagnosed with hepatocellular carcinoma, 73 (34.1%) eventually underwent orthotopic liver transplantation. The majority of patients who did not undergo orthotopic liver transplantation were deceased or lost to follow-up (47.5%), with 14 of 141 (9.9%) currently listed for transplantation. Among transplanted patients, 21 of 73 (28.8%) were considered high-risk candidates. All 21 patients were downstaged to within Milan criteria with an alpha-fetoprotein <400 ng/mL before orthotopic liver transplantation, through locoregional therapies. Recurrence of hepatocellular carcinoma was higher but acceptable between downstaged high-risk and traditional candidates (9.5% vs 1.9%; P > .05) at a median follow-up period of 17 months. Downstaged high-risk candidates had a similar overall survival compared with those transplanted within Milan criteria (log-rank P > .05). Conclusions In highly selected cases, patients with hepatocellular carcinoma outside of traditional criteria for orthotopic liver transplantation may undergo downstaging therapy in a multidisciplinary fashion with excellent post-transplant outcomes. These data support an aggressive downstaging approach for selected patients who would otherwise be deemed ineligible for transplantation. Orthotopic liver transplantation is a curative treatment for hepatocellular carcinoma within Milan criteria, but these criteria preclude many patients from transplant candidacy. Recent studies have demonstrated that downstaging therapy can reduce tumor burden to meet conventional criteria. The present study reports a single-center experience with tumor downstaging and its effects on post–orthotopic liver transplantation outcomes. All patients with hepatocellular carcinoma who were evaluated by our multidisciplinary liver services team from 2012 to 2016 were identified (N = 214). Orthotopic liver transplantation candidates presenting outside of Milan criteria at initial radiographic diagnosis and/or an initial alpha-fetoprotein >400 ng/mL were categorized as at high risk for tumor recurrence and post-transplant mortality. Of the 214 patients newly diagnosed with hepatocellular carcinoma, 73 (34.1%) eventually underwent orthotopic liver transplantation. The majority of patients who did not undergo orthotopic liver transplantation were deceased or lost to follow-up (47.5%), with 14 of 141 (9.9%) currently listed for transplantation. Among transplanted patients, 21 of 73 (28.8%) were considered high-risk candidates. All 21 patients were downstaged to within Milan criteria with an alpha-fetoprotein <400 ng/mL before orthotopic liver transplantation, through locoregional therapies. Recurrence of hepatocellular carcinoma was higher but acceptable between downstaged high-risk and traditional candidates (9.5% vs 1.9%; P > .05) at a median follow-up period of 17 months. Downstaged high-risk candidates had a similar overall survival compared with those transplanted within Milan criteria (log-rank P > .05). In highly selected cases, patients with hepatocellular carcinoma outside of traditional criteria for orthotopic liver transplantation may undergo downstaging therapy in a multidisciplinary fashion with excellent post-transplant outcomes. These data support an aggressive downstaging approach for selected patients who would otherwise be deemed ineligible for transplantation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小马儿发布了新的文献求助10
刚刚
刚刚
查拉图斯特拉如是说完成签到,获得积分10
刚刚
好hshs发布了新的文献求助10
刚刚
上官若男的应助被yy采纳,获得10
刚刚
DUMPLINGS完成签到,获得积分10
1秒前
碧蓝梦寒发布了新的文献求助10
2秒前
3秒前
4秒前
阳光的安南完成签到,获得积分10
5秒前
TEDDY发布了新的文献求助10
5秒前
weinian完成签到,获得积分20
5秒前
我是老大的应助被00采纳,获得10
5秒前
余叶完成签到,获得积分10
7秒前
小马儿完成签到,获得积分10
8秒前
8秒前
研友_VZG7GZ的应助被清水飒采纳,获得10
8秒前
Hello的应助被科研通管家采纳,获得10
8秒前
chen发布了新的文献求助20
8秒前
Deiog发布了新的文献求助10
9秒前
molihuakai的应助被科研通管家采纳,获得10
9秒前
9秒前
seal发布了新的文献求助10
9秒前
慕青的应助被科研通管家采纳,获得10
9秒前
9秒前
9秒前
情怀的应助被科研通管家采纳,获得10
9秒前
Ava的应助被科研通管家采纳,获得10
9秒前
斯文败类的应助被科研通管家采纳,获得10
9秒前
竹园发布了新的文献求助10
9秒前
小马甲的应助被科研通管家采纳,获得10
10秒前
打打的应助被科研通管家采纳,获得10
10秒前
秋风的应助被科研通管家采纳,获得10
10秒前
10秒前
10秒前
科目三的应助被科研通管家采纳,获得10
10秒前
10秒前
司空老五完成签到,获得积分20
12秒前
12秒前
上官若男的应助被zcm1314521采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172327
求助须知:如何正确求助?哪些是违规求助? 9564990
关于积分的说明 21777687
捐赠科研通 7763968
什么是DOI,文献DOI怎么找? 3431223
关于科研通互助平台的介绍 2555098
邀请新用户注册赠送积分活动 2476246